NEW YORK, Dec. 27, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of StoneMor Partners L.P. securities (NYSE:STON) from January 19, 2012 through October 27, 2016, inclusive (the “Class Period”) of the important January 20, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for StoneMor investors under the federal securities laws.
To join the StoneMor class action, go to http://rosenlegal.com/cases-1004.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the Complaint, StoneMor made false and misleading statements and/or failed to disclose during the Class Period that: (1) StoneMor’s reported non-GAAP financial metrics were materially misleading and concealed the truth about the Company’s actual financial condition; and (2) the primary purpose of StoneMor’s regular debt and equity offerings were to pay distributions to unitholders rather than to pay down indebtedness under StoneMor’s revolving credit facility as publicly stated. As a result, StoneMor’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1004.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Shell M&A Chief Exits After BP Takeover Proposal Rejected
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 



